✦ LIBER ✦

Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers

✍ Scribed by S. de Rave; R.A. Heijtink; M. Bakker-Bendik; J. Boot; S.W. Schalm

Book ID: 119152238
Publisher: Elsevier Science
Year: 1994
Tongue: English
Weight: 300 KB
Volume: 12
Category: Article
ISSN: 0264-410X
DOI: 10.1016/0264-410x(94)90313-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and Immunogenicity of a Yeast-Der

Safety and Immunogenicity of a Yeast-Derived Recombinant Hepatitis B Vaccine in Bulgarian Newborns

✍ M. Kojouharova; P. Teoharov; T. Bahtchevanova; I. Maeva; A. Eginlian; M. Deneva 📂 Article 📅 2001 🏛 Springer-Verlag 🌐 English ⚖ 81 KB

Clinical evaluation of low dose intrader

Clinical evaluation of low dose intradermally administered hepatitis B vaccine: a comparison of plasma-derived and recombinant yeast-derived vaccines

✍ G. Söyletir; E. Bahçeci; E. Akoğlu; U. Soyoğul; R.A. Lawrance 📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 339 KB

Comparative evaluation of the immunogeni

Comparative evaluation of the immunogenicity of yeast-derived (recombinant) and plasma-derived hepatitis B vaccine in infants

✍ Subrat K. Panda; Rajagopal Ramesh; Kanury V. S. Rao; Asha Gupta; Arie J. Zuckerm 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 661 KB

## Abstract The immunogenicity of plasma‐derived (HB Vax, MSD) and recombinant hepatitis B virus (Engerix B, SKF) vaccines was evaluated in infants born to hepatitis B virus carrier mothers. The vaccination was carried out at 1 day, 1 month, and 6 months of age using 10 μg of the vaccine given intr

Immunogenicity of a recombinant, yeast-d

Immunogenicity of a recombinant, yeast-derived, anti-hepatitis-B vaccine after alternative dosage and schedule vaccination in Pakistani children

✍ Dure Samin Akram; Sajid Maqbool; Dure Shawar Khan; Rafat Jafri; Sajid Randhawa; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 102 KB

Recombinant-yeast-derived hepatitis b va

Recombinant-yeast-derived hepatitis b vaccine in healthy adults: Safety and two-year immunogenicity of early investigative lots of vaccine

✍ Lynn Butterly; Eloise Watkins; Jules L. Dienstag 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 554 KB

We tested the safety and long-term immunogenicity of two of the early investigative lots of a recombinant-yeast-derived hepatitis B vaccine in immunocompetent adults. Three 10-micrograms doses of recombinant hepatitis B vaccine (Merck Sharp & Dohme Research Laboratories, West Point, PA) were adminis

Improved immunogenicity in mice of a mam

Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines

✍ D. Shouval; Y. Ilan; R. Adler; R. Deepen; A. Panet; Z. Even-Chen; M. Gorecki; W. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 957 KB